Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study 英文参考文献.docVIP

下载本文档

2
0
约4.17万字
约 8页
2017-05-11 发布于上海
举报
版权申诉

Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study 英文参考文献.doc

1、本文档共8页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study 英文参考文献

EstrogenReceptorStatusinRelationtoRiskof ContralateralBreastCancer–APopulation-BasedCohort Study MariaE.C.Sandberg1*,PerHall1,MikaelHartman1,2,3,AnnaL.V.Johansson1,SandraEloranta1, AlexanderPloner1,KamilaCzene1 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 2Saw Swee Hock School of Public Health, Singapore, Singapore, 3DepartmentofSurgery,NationalUniversityofSingapore,Singapore,Singapore Abstract Background: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated with risk of metachronous (non-simultaneous) contralateral breast cancer (CBC), and to what extent endocrine therapy affects this association. Methods:WestudiedtheeffectofER-statusofthefirstcancerontheriskofCBCoverall,andfordifferentER-subtypesof CBC, using a large, population-based cohort. The cohort consisted of all women diagnosed with breast cancer in the Stockholm region 1976–2005; 25715 patients, of whom 940 suffered CBC. The relative risk was analyzed mainly using standardizedincidenceratios(SIR). Results:WomenwithbreastcancerhadadoubledriskofCBCcomparedtotheriskofbreastcancerinthegeneralfemale population (SIR: 2.22 [2.08–2.36]), for women with a previous ER-positive cancer: SIR=2.30 (95% CI:2.11–2.50) and for womenwithapreviousER-negativecancer:SIR=2.17(95%CI:1.82–2.55).TherelativeriskofER-positiveandER-negative CBCwasverysimilarforwomenwithER-positivefirstcancer(SIR=2.02[95%CI:1.80–2.27]andSIR=1.89[95%CI:1.46–2.41] respectively) while for patients with ER-negative first cancer the relative risk was significantly different (SIR=1.27 [95% CI:0.94–1.68]forER-positiveCBCandSIR=4.96[95%CI:3.67–6.56]forER-negativeCBC).PatientswithER-positivefirstcancer who received hormone therapy still had a significantly higher risk of CBC than the risk of breast cancer for the general femalepopulation(SIR=1.74[95%CI:1.47–2.03]). Conclusion:TheriskofCBCforabreastcancerpatientisincreasedtoabouttwo-fold,comparedtotheriskofbreastc